The loss-of-function rs4374383 G > A variant in Myeloid-epithelial-reproductive Tyrosine Kinase (MERTK) gene has been linked to hepatic fibrosis in chronic liver diseases. MERTK is expressed by immune and non-immune cells involved in inflammation, metabolism and vascular homeostasis. We assessed the impact of MERTK rs4374383 G > A variant on nonalcoholic fatty liver disease (NAFLD) incidence and severity and on glucose and lipid metabolism. We followed-up 305 healthy nonobese nondiabetic, metabolic syndrome-free insulin sensitive participants in a population-based study, characterized for MERTK G > A polymorphism, adipokine profile and inflammatory markers. An independent cohort of 69 biopsy-proven nondiabetic NAFLD patients and 69 healthy controls underwent indirect calorimetry, an OGTT with Minimal Model analysis of glucose homeostasis, and an oral fat tolerance test with measurement of plasma lipoproteins, adipokines, MCP-1, and of Nuclear Factor (NF)-jB activation in circulating mononuclear cells (MNCs). In the longitudinal cohort, MERTK G > A polymorphism protected against 9-year incident NAFLD (OR:0.48,95%CI:0.26-0.79) and diabetes (OR: 0.47, 95% CI: 0.19-0.87). In the cross-sectional cohort, MERTK A-allele carriers had higher fat oxidation rates and tissue insulin sensitivity. Despite comparable fastign and postprandial lipid profiles, MERTK A-allele carriers showed lower resistin and MCP-1 responses, milder MNC NF-jB activation, and a higher postprandial adiponectin response to fat, which predicted tissue insulin resistance hepatocyte apoptosis and liver histology. MERTK G > A variant affects liver disease, nutrient oxidation and glucose metabolism in NAFLD. The modulation of adipokine, chemokine and pro-inflammatory MNC activation in response to fat ingestion may contribute to the observed effects on liver and metabolic disease.
Introduction
Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis (SS) to steatosis plus necroinflammation (nonalcoholic steatohepatitis, NASH). NASH is projected to be the leading cause of liver transplantation by 2020 and NAFLD confers an increased risk of type 2 diabetes (T2DM) and cardiovascular disease (CVD), through mechanisms potentially involving adipokine and lipid dysregulation (1) . Although scarce prospective data link the risk of developing NAFLD to baseline metabolic syndrome, insulin resistance and overweight (2) not every insulin resistant or obese subject develops NAFLD or progressive NASH and fibrosis, implying additional genetic and/or environmental factors are required to develop progressive liver disease. Among environmental factors, dietary fat excess has been consistently linked to the risk of CVD and T2DM in the general population (3) , while in NAFLD epidemiological data are more controversial (4) . Among genetic factors, the patatin-like phospholipase-3 (PNPLA3) rs738409 C > G single nucleotide polymorphism (SNP) has been linked to the presence and severity of NAFLD (5) at the population level. However, known genetic and environmental factors are insufficient to accurately predict individual risk of liver disease progression and cardio-metabolic complications. Furthermore, data connecting these SNPs to NAFLD come from cross-sectional studies, and it is unclear whether the association between different SNPs and NAFLD is direct or mediated by the development of other conditions like insulin resistance and obesity.
Collectively, these data highlight the need for a deeper knowledge of gene-environment interactions to stratify individual liver-related and cardio-metabolic risk in NAFLD. In crosssectional studies, the loss-of-function rs4374383 G > A variant in the intron region of the myeloid-epithelial-reproductive tyrosine kinase (MERTK) locus protected against liver fibrosis in chronic hepatitis C and NAFLD (6, 7) . This effect has been suggested to be mediated by a reduced hepatic stellate cell activation associated with the MERTK A-allele variant (7) . MERTK is a receptor tyrosine kinase of the tumour-associated macrophage (TAM) family, which was originally identified in monocyte-derived cells and Kupffer cells, where it regulates cytoskeletal organization, migration, phagocytosis and efferocytosis (8, 9) . However, MERTK is also physiologically expressed by other cell populations, including adipocytes, where its activation has been involved in high fat diet-induced adiposity, inflammation, and insulin resistance (10) (11) (12) , by endothelial cells (ECs), where its activation triggers proinflammatory EC activation, platelet aggregation and thrombus formation (8) , and by enterocytes and miocytes (13) , where its biological role is unknown. Further supportive of a key role of this tyrosine kinase in metabolism, a genome-wide association study (GWAS) linked MERTK rs6726639 C > A variant to fasting glucose-related phenotype (14) . Collectively, these data suggest MERTK may be implicated in a wide range of metabolic and inflammatory functions beyond liver fibrosis, which may contribute to NAFLD pathogenesis and to NAFLD-associated cardio-metabolic phenotype.
In this study, we: 1) longitudinally assessed the impact of MERTK rs4374383 G>A variant on NAFLD incidence and severity and on NAFLDassociated metabolic risk in initially healthy, insulin sensitive, non-obese, nondiabetic subjects without metabolic syndrome. 2) investigated mechanisms connecting MERTK SNPs rs4374383 G>A SNP to liver injury, glucose and lipid metabolism in an independent cohort of biopsy-proven NAFLD patients and healthy controls.
Methods

Subjects
Based on available data showing a MERTK rs4374383 G > A SNP A allele frequency of 48% and a prevalence of NAFLD of 25% (1, 15) , assuming an effect size of ! 1.5(OR for NAFLD across genotypes) and allowing for a 10% drop-out rate, at least 297 subjects were needed to detect a significant (P < 0.05) difference in NAFLD incidence across MERTK genotypes with a power of 80%. Among 1512 Caucasians aged 45-64 years participating in a metabolic survey in the province of Asti (North-Western Italy) in 2004-2005 (previously described) (16) , 322 randomly selected subjects gave informed consent to be included in the study. At baseline, all were in good general health, with normal findings on medical history, physical examination, chemical screening battery and abdomen ultrasound. Subjects with diabetes, obesity, metabolic syndrome, insulin resistance, known CVD, significant alcohol consumption (>20 g/d in males and >10 g/d in females, assessed by a detailed inquiry of patients and relatives and a validated questionnaire filled in daily for one week by the patients), liver enzyme elevation (including serum ALT > 30 IU/l in men and >20 IU/l in women, according to recently proposed cut-offs that have a > 95% negative predictive value for the presence of steatosis, were excluded from the study, which was approved by the local Ethics Committee and conformed to the Helsinki Declaration.
Baseline data collected during the period 2004-2005 included: measurements of weight, height, and waist circumference, blood pressure following a uniform protocol; dietary and physical activity record, routine biochemistry, upper abdomen ultrasound (detailed below).
Frozen serum samples collected from all participants at entry were stored at À80 C for genetic and biochemical analyses.
From June 2013 to June 2015, participants in the baseline survey were submitted to follow-up evaluation: all anthropometric, dietary and physical activity records, abdomen ultrasound and biochemical analyses were repeated at the end of follow-up.
Definitions
The diagnosis of NAFLD was based on upper abdomen ultrasound and exclusion of competing causes of steatosis according to current guidelines (detailed in Supplementary Appendix) (17) . Diabetes was defined by a fasting plasma glucose (FPG) !126 mg/dl or 2-h plasma glucose !200 mg/dl during an OGTT or by drug treatment for elevated plasma glucose. Obesity was defined by a BMI ! 30 kg. Insulin resistance was defined by a homeostasis model assessment of insulin resistance (HOMA-IR) index !2, a cut-off closely correlating with clamp measures in Northern Italian subjects and with OGTT-derived indices of insulin sensitivity in our subjects with NAFLD (18) . Metabolic syndrome (MS) was defined according to the joint IDF/NHLBI/ AHA/IAS/IASO definition (detailed in legend to Table 1 ).
Dietary and physical activity record
Subjects were instructed to fill in a 7-day validated and reproducible dietary questionnaire during an individual training session with a nutritionist; a list of foods was designed, for each item Met Sy: metabolic syndrome according to the joint statement of American Heart association (AHA), International Diabetes Federation (IDF) and National Heart Lung and Blood Institute (NHLBI), requires the presence of !3 of the following criteria:
• -abdominal obesity: waist circumference ! 102 cm(males) and !88 cm(females).
• -high triglycerides: !150 mg/dl or on drug treatment for elevated triglycerides.
• -low HDL-C: <40 mg/dl (males) or <50 mg/dl (females) or on drug treatment for reduced HDL-C.
• -hypertension: systolic BP ! 130 and/or diastolic BP ! 85 mm Hg or on drug treatment.
• -high fasting plasma glucose (FPG): FPG !100 mg/dl or on drug treatment for elevated glucose. different portion sizes were specified according to the EPIC study (19 Patients were interviewed about smoking habits and completed the Minnesota-Leisure-Time-Physical-Activity questionnaire (21) . The physical activity level was calculated as the product of duration and frequency of each activity (in h/week), weighed by an estimate of the metabolic equivalent of the activity, and summed for activities performed.
Adipokines and inflammatory markers
As MERTK is an emerging regulator of adipocyte development and function, we measured circulating adipokines adiponectin and resistin and C-reactive protein (CRP) (detailed in Supplementary Appendix).
Pro-antioxidant status
As oxidative and nitrosative stress play a crucial role in liver and cardio-metabolic disease (22), we measured plasma nitrotyrosine (NT) and total antioxidant status (TAS) (detailed in Supplementary Appendix).
Genetic analyses
Participants were genotyped for MERTK rs4374383 G > A and PNPLA3 rs738409 C > G variants with the real-time allele discrimination method, using TaqMan Allelic Discrimination Assay (Applied Biosystems, Foster city, CA). The TaqMan genotyping reaction was run on an 7300HT Fast Real-Time PCR (Applied Biosystem).
We also genotyped our population for MERTK rs6726639 C > A variant, previously linked to fasting glucose traits (14) and for apoE genotype, a key regulator of lipoprotein metabolism which has been previously linked to the risk of NAFLD (5) (detailed in Supplementary Appendix).
Impact of mertk G > a polymorphism on substrate oxidation rates, glucose and lipid metabolism
We next investigated potential mechanisms linking MERTK G > A variant to liver injury, glucose and lipid metabolism in an independent cross-sectional cohort. Based on previous data, at least 23 subjects per each genotype were needed to detect significant differences in postprandial glucose and lipid metabolism across MERTK G > A SNP (23) : an independent cohort of 69 biopsy-proven NAFLD patients attending our Turin Hepatological Unit and 69 healthy age-, gender-and MERTK G > A genotype-matched volunteers (controls), underwent indirect calorimetry, a standard OGTT and an oral fat tolerance test (OFTT).
NAFLD was diagnosed and staged or ruled out (in controls) as previously described.
In this part of the study, diabetic patients were excluded and patients and controls were matched for BMI since diabetes and differences in adiposity may modify the effect of MERTK on liver disease, glucose homeostasis, adipokines and lipoprotein metabolism (18).
Anthropometry and indirect calorimetry
Body fat % was estimated by the bioelectrical impedance analysis (BIA) method (TBF-202, Tanita, Tokyo, Japan), closely correlating with dual X ray absorption (24) .
After an overnight fast, participants underwent indirect calorimetry measurement of oxygen consumption (VO2) and carbon dioxide production (VCO2) using an open circuit indirect calorimeter with a ventilated-hood system (Deltatrac TM II, Datex Instrumentarium Corp., Helsinki, Finland)(see Supplementary Appendix). Whole-body respiratory quotient (RQ) and non-proteic RQ (npRQ) were calculated as VCO2/VO2. Resting energy expenditure (REE), and whole-body CHO oxidation (CHO ox ) and fat oxidation rates (Fat ox ) were calculated using stoichiometric equations and appropriate energy equivalents and corrected for fat-free mass (FFM) (25) .
Glucose homeostasis
Minimal Model analysis of plasma glucose, insulin and C-peptide during the OGTT yielded the following parameters of glucose homeostasis (see Supplementary Appendix): whole-body insulin sensitivity index (OGIS); hepatic and muscle insulin resistance; 2 indexes of b-cell function the CP-genic index, CGI and the adaptation index (AI), which relates b-cell insulin secretion to insulin resistance and were previously validated against frequently sampled intravenous glucose tolerance test (FIVGTT) MINIMAL MODEL parameters (26) . Adipose tissue insulin resistance (IR) index was calculated as fasting free fatty acids (FFA) x fasting insulin (27) .
Oral fat tolerance test (OFTT)
Western populations spent most of their day in the postprandial state and accordingly postprandial lipaemia is an emerging CVD risk factor (27) . As MERTK protein is expressed by cells with a key role in lipid metabolism, inflammation and vascular homeostasis, we hypothesized MERTK G > A polymorphism modulates the dietary fat metabolism and lipotoxicity. Biopsyproven NAFLD patients and controls underwent an OFTT, and the following parameters were measured (detailed in Supplementary Appendix): 1) Plasma lipids and lipoproteins: Total cholesterol (Chol), triglyceride (Tg), FFA, HDL-C were measured by automated enzymatic methods. Triglyceride-rich lipoproteins (TRLPs) were isolated through preparative ultracentrifugation and subfractionated and their apoB100 and apoB48 content were measured. 2) Oxidative stress markers: LDL conjugated dienes, as markers of oxidized low-density lipoproteins (oxLDLs), were determined by capillary electrophoresis and plasma TAS was measured as detailed in Supplementary Appendix. 3) Adipokines and chemokines: Adiponectin, resistin and monocyte chemoattractant protein-1 (MCP-1), key players in metabolism, nutritionally induced inflammation and liver injury (28), were measured a solid-phase sandwich enzyme-linked immunosorbent assay ELISA (R&D Systems Europe, Abingdon, UK). 4) Nuclear Factor(NF)-jB activation in mononuclear cells (MNCs) . Activation of the pro-inflammatory NF-jB pathway in mononuclear cells (MNCs) is central for metabolic inflammation, insulin resistance and liver injury (29) . As NF-jB is a direct downstream target of MERTK, and oxidized lipoproteins modulate MERTK activity (30,31), we measured NF-jB activation in circulating MNCs during the OFTT. Brifely, blood samples were collected in sodium EDTA, MNCs were isolated by gradient centrifugation and total cell lysates and nuclear extracts were prepared from freshly isolated MNCs. NF-jB DNA binding activity was measured with the NF-kBp50/p65 transcription factor enzyme-linked immunosorbent assay(ELISA) kit (Cayman Chemical, Ann Arbor MI, USA)(detailed in Supplementary Appendix) (32) . The method separately detects and quantitates p65 and p50 in the nuclear and cytoplasmic fractions: specific NF-jB activation is demonstrated by translocation of NF-jB protein from the cytoplasm to nucleus as measured using ELISA. The nuclear NF-jB(p65) and NF-jB(p50) DNA-binding activity were quantitated and expressed as both %DNA binding activity (in absolute terms) and as nuclear-to-cytoplasm NF-jB(p65) ratio and nuclear-to-cytoplasm NF-jB(p50) ratio. 5) Markers of hepatocyte apoptosis. Plasma cytokeratin-18 (CK-18) fragments, an hepatocyte-specific marker of apoptosis and hepatic necro-inflammation in NASH (2), were measured by M30-Apoptosense ELISA kit.
Statistical analysis
Participants with and without follow-up visits were compared to determine the appropriateness of an analysis based on participants with complete data only. Based on the results of univariate analysis, a logistic regression model was used to identify independent predictors of incident NAFLD, NASH and advanced fibrosis, of incident T2DM and of markers of subclinical atherosclerosis at the end of followup. Variables were selected from parameters which differed between NAFLD developers and non-NAFLD developers at baseline and/or during follow-up. In the cross-sectional cohort, the area under the curve (AUC) and incremental AUC (IAUC) of parameters measured during the OGTT and the OFTT in NAFLD patients and controls were computed by the trapezoid method. In this cohort, univariate and subsequent multivariate logistic regression analysis were used to identify predictors of glucose and lipid homeostasis parameters and of liver histology in NAFLD patients. Quartiles of continuous variables were considered in all analyses. Data were expressed as mean 6 SEM. (STATISTICA software, 5.1, Statsoft Italia, Padua, Italy).
Results
Follow-up cohort: baseline and end-of-follow-up subjects characteristics
After a mean follow-up period of 9.2 6 0.5 years, data on 305 participants were available for examination ( Table 1 ). The 17 (5.6%) individuals lost at follow-up did not significantly differ in baseline anthropometric, lifestyle, clinical or biochemical feature from the other participants included in the analysis. At the end of follow-up, 75 (24%) subjects developed NAFLD. At the end of follow-up, NAFLD patients had significantly higher BMI, C-reactive protein, markers of endothelial dysfunction, HOMA-IR, and resistin and lower plasma adiponectin and TAS levels than non-NAFLD developers; 13% NAFLD patients vs. 2% non-NAFLD developers had T2DM (P ¼ 0.0006) and 32% NAFLD patients vs. 16% non-NAFLD developers had high fasting plasma glucose (FPG) (P ¼ 0.0008) ( Table 1) . MERTK GG carriers were 28% in non-NAFLD developers vs. 47% in NAFLD developers (P ¼ 0.0009), heterozygous AG carriers were 37% in non-NAFLD developers vs. 33% in NAFLD developers (P ¼ 0.658) and homozygous AA b P < 0.01 vs. subjects with the other MERTK genotypes with the same condition (NAFLD or controls). c P < 0.05 vs. GG genotype group with the same condition (NAFLD or controls). d P < 0.01 vs. subjects with GG genotype with the same condition (NAFLD or controls). e P < 0.05 vs. subjects with GA genotype group with the same condition (NAFLD or controls). f P < 0.01 vs. subjects with GA genotype within the same group (NAFLD or controls). g P < 0.05 vs. all control groups.
Data are presented as mean 6 SEM, unless otherwise specified.
Glucose: mg/dl *0.0555 ¼ mmol/l; insulin: mg/ml*6.945 ¼ pmol/l; C-pep: ng/ml*0.331 ¼ nmol/l.
Abbreviations. BP: blood pressure; total C: total cholesterol; HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; NAS: NAFLD Activity Score (sum of steatosis, lobular inflammation and ballooning scores); Tg: triglyceride; IGR: impaired glucose regulation; IFG: impaired fasting glycaemia; IGT: impaired glucose tolerance.
Severe steatosis was defined as involving >66% hepatocytes; NASH was defined according to Brunt definition; Advanced steatosis was defined as stage 3 fibrosis(no patient had cirrhosis on liver biopsy).
Met Sy: metabolic syndrome according to the joint statement of AHA, IDF and NHLBI, requires the presence of !3 of the following criteria:
• -high triglycerides: !150 mg/dl (1.7 mmol/l) or on drug treatment for elevated triglycerides.
• -low HDL-C: <40 mg/dl (1.0 mmol/l) (males) or <50 mg/dl (1.3 mmol/l) (females) or on drug treatment for reduced HDL-C.
• -high fasting plasma glucose(FPG): FPG !100 mg/dl (5.6 mmol/l) or on drug treatment for elevated glucose.
carriers were 35% in non-NAFLD developers vs. 20% in NAFLD developers (P ¼ 0.025) ( Table 1 ). PNPLA3 G-allele carriers were also more frequent in NAFLD developers than in non-NAFLD developers.
MERTK G/A genotype frequencies were in Hardy-Weinberg equilibrium and the minor A-allele frequency (49%) were consistent with published reports in Caucasians (6, 7, 15) . At baseline, there was no significant difference in any other genetic, anthropometric, lifestyle, clinical or biochemical feature between NAFLD developers and non-NAFLD developers or among MERTK genotypes (Table 1, Supplementary Appendix Table S1 ). There was also no significant difference in physical activity (Table 1) or dietary habits (not shown) between NAFLD developers and non-NAFLD developers throughout the study.
Follow-up cohort: impact of MERTK G > a SNP on incident NAFLD and T2DM
The presence of MERTK A allele (GA/AA carriers vs. GG carriers) protected against incident NAFLD and diabetes (Table 2) . Results were similar when analysing the risk for incident NAFLD of AA vs. GG/GA carriers, in line with previous studies (7-9): OR for NAFLD ¼ 0.46; 95% CI: 0.23-0.71; P ¼ 0.007.
The presence of MERTK A allele (GA/AA carriers vs. GG carriers) was also associated with a lower increase in circulating CRP at the end of follow-up (Table 2) .
Cross-sectional cohort: subject characteristics
Characteristics of NAFLD patients and controls in the crosssectional cohort are reported in Table 3 . Within patients and controls, the presence of MERTK A allele was associated with lower HOMA-IR, lower serum levels of markers of oxidative stress and inflammation. Remarkably, in both patients and controls the proportion of energy derived from fat and CHO oxidation differed across MERTK genotypes: MERTK A-allele carriers had lower RQ and npRQ that G allele carriers, indicating they oxidize predominantly fat and less CHO (Table 3) . MERTK A allele was also associated with milder histological severity of NAFLD (Table 3) .
Cross-sectional cohort: impact of MERTK SNP on glucose homeostasis
NAFLD patients as a group had more severe whole-body and tissue insulin resistance than controls (Table 4 ). In both NAFLD patients and controls, the presence of MERTK A allele was dosedependently associated with lower whole-body and tissue insulin resistance, i.e., whole-body, hepatic, muscle and adipose tissue insulin resistance were lower in AA homozygotes than in GA heterozygotes, and lower in GA heterozygotes than in GG homozygotes (Table 4) .
Cross-sectional cohort: impact of MERTK SNP on oral fat load parameters NAFLD patients as a group had a higher postprandial lipemia, nefaemia and oxLDL response than healthy controls (Table 5) . MERTK G > A variant did not affect fasting and postprandial triglyceride, triglyceride-rich lipoprotein subfractions, FFA, HDL-C and oxLDL levels. MERTK G > A variant did not affect fasting and postprandial triglyceride-rich lipoprotein subfractions of either intestinal or hepatic origin (not shown). Conversely, MERTK G > A polymorphism extensively modulated postprandial TAS, adipokine, chemokine MCP-1 and CK-18 fragment levels and NF-jB activation in MNCs in response to fat ingestion: in patients and controls, Compared with MERTK G allele, A allele was dose-dependently associated with lower postprandial resistin, MCP-1, CK-18 fragment levels and with higher postprandial TAS and adiponectin levels in response to fat ingestion (Table 5 , Fig. 1) . Compared with MERTK G allele, the presence of MERTK Aallele was associated with a blunted NF-jB activation in MNCs, as expressed as both nuclear-to-cytoplasm NF-jB(p65) and NFjB(p50) and ratio and as nuclear NF-jB(p65) and nuclear NFjB(p50) %DNA binding activity [for simplicity, only NF-jB(p65) nuclear-to-cytoplasm ratio and nuclear NF-jB(p65) %DNA binding activity are reported in Table 5 and in Fig. 1 ].
Cross-sectional cohort: predictors of substrate oxidation rates, glucose homeostasis, liver histology and OFTT parameters on logistic regression Whole-body Fat ox was independently predicted by IAUC adiponectin (OR ¼ 1.79, 95%CI: 1.24-2.55, P ¼ 0.009). (Table 6 ) Table 4 Glucose homeostasis parameters of biopsy-proven NAFLD patients and controls, grouped according to MERTK G > A genotype in the cross-sectional cohort (n ¼ 138) Dat are presented as mean 6 SEM. MERTK G > A SNP independently predicted OGIS, hepatic and adipose insulin resistance, while muscle insulin sensitivity was independently predicted by postprandial adiponectin response to fat ingestion.
The presence of severe steatosis was predicted by postprandial adiponectin and MCP-1 responses, the presence of NASH was predicted by MERTK G > A SNP and by postprandial adiponectin and NF-jB activation in MNCs, and the presence of advanced (stage 3) fibrosis was predicted by MERTK G > A SNP and by postprandial NF-jB activation in MNCs.
Finally, MERTK G > A SNP independently modulated postprandial adipokine and MCP-1 responses, and hepatocyte apoptosis activation and NF-jB activation in MNCs in response to fat ingestion.
Discussion
We analysed the impact of MERTK G/A SNPs on liver disease, glucose and lipid metabolism in NAFLD. The main results are the following: 1) In nonobese nondiabetic, insulin sensitive subjects, MERTK G>A SNP predicted NAFLD incidence and severity, incident diabetes and changes in levels of circulating markers of CVD risk at the end of follow-up.
2) The association between MERTK G>A SNP and NAFLD was replicated in an independent cohort of biopsy-proven NAFLD patients and controls, where this SNP modulated nutrient oxidation rate and insulin resistance. this SNP on liver histology, nutrient oxidation rates and glucose homeostasis.
Recent cross-sectional data supported a protective role of the loss-of-function MERTK G > A variant on HSC activation and liver fibrosis in chronic hepatitis C and NAFLD (6, 7) .
Growing experimental evidence suggests a key regulatory role for MERTK in metabolism, vascular homeostasis and inflammation: we therefore investigated the impact of MERTK G > A SNP on the development and severity of NAFLD and on NAFLD-associated cardio-metabolic risk profile, and explored potential mechanisms.
We found in initially healthy, nononbese, nondiabetic insulin sensitive individuals, MERTK G > A variant protected against 9-year NAFLD incidence and severity and against incident T2DM. Furthermore, MERTK A allele carriers showed less weight gain and a lower increase in circulating markers of CVD risk.
In the mechanistic part of the study, we showed MERTK G > A variant is associated with enhanced fat oxidation and insulin sensitivity and with a blunted inflammatory response to fat ingestion.
Despite comparable postprandial plasma lipid and lipoprotein profile across MERTK genotypes, MERTK A allele was associated with a higher adiponectin response, coupled with lower pro-inflammatory resistin and MCP-1 responses and a blunted NF-jB activation in circulating MNCs. The impact of MERTK G > A variant on dietary fat-induced inflammation is a novel finding and may contribute to the observed clinical impact of this SNP on liver disease and metabolic parameters (Table 6) . Growing evidence suggests dietary fat intake triggers an acute, postprandial pro-inflammatory adipokine and chemokine response, and these acute, repetitive pro-inflammatory stimuli eventually elicit a chronic nutritionally induced inflammation, which is central for the development of obesity-related complications (31) . Additionally, experimental data suggest NASH is characterized by an adaptive failure to dietary fat (33) , but genetic modifiers of this maladaptive response to fat ingestion are unclear (34) . NF-jB is a key mediator of nutritionally-induced inflammation, as it mediates many pro-inflammatory effects of saturated fatty acids, glucose and oxidized LDLs (35) . NF-jB activation triggers the release of pro-inflammatory adipokines and chemokines by adipocytes and MNCs Experimental evidence shows NF-jB is a downstream target of MERTK, which in turn is directly activated by oxLDLs and lipid oxidation products in MNCs (30,31): we showed MERTK A allele carriers have a blunted fatinduced pro-inflammatory NF-jB activation in MNCs in response to postprandial oxLDL elevation (Tables 5 and 6 ). The blunted NF-jB activation in MNCs may also partially explain the anti-inflammatory impact of MERTK G > A variant on adipokine and MCP-1 responses to fat (Tables 5 and 6 ; Fig. 1 ), in line with existing literature suggesting a role for MNC activation on adipose tissue inflammation and dysfunction (36) . One can also hypothesize a direct role of MERTK in adipocytes in regulating adipokine and MCP-1 secretion, as MERTK G > A predicted adipokine and MCP-1 responses independently of MNCs' NF-jB activation (Table 6 ).
An intriguing finding of our study was the independent association of MERTK G > A SNP with endothelial dysfunction markers (Tables 2 and 6 ). These data are consistent with mounting experimental evidence linking MERTK activation to endothelial cell activation and thrombus formation, which are prevented by pharmacological or genetic MERTK inactivation (8) .
From a clinical perspective, further research in this field could provide novel therapeutic opportunities for the prevention and treatment of NAFLD-related complications and diabetes. Within this context, it should be noted that potent, specific small molecule inhibitors of MERTK, like UNC569, yielded promising preclinical results for the treatment of leukaemia (37) and might be evaluated in the metabolic field, as well.
In conclusion, we prospectively linked MERTK G > A SNP to the development and severity of NAFLD and to NAFLDassociated cardio-metabolic derangement. We demonstrated this SNP affects nutritionally induced inflammation which may contribute to liver and cardio-metabolic disease.
If confirmed by larger studies in diverse ethnicities, our findings may have screening and therapeutic implications: MERTK G > A variant may help stratify liver-related and cardio-metabolic risk of NAFLD patients; more importantly, in light of the extensive involvement of MERTK in metabolic, inflammatory and vascular homeostasis, our findings prompt investigation of recently discovered MERTK small molecule inhibitors for treating NASH and NASH-associated cardio-metabolic disorders (8, (38) (39) (40) (41) .
Our study has strengths and limitations: strengths are the careful selection, the thorough characterization of participants and the histological characterization of NAFLD, the limitations are the relatively small sample size, and the ultrasonographic method to screen for NAFLD, which may have missed some cases of milder fat infiltration. However, we used standardized criteria with significantly improved diagnostic accuracy for detecting even minor degrees of steatosis (23) , and the combination of ultrasonography with recently proposed lower ALT cutoff values should have improved individuation of even milder cases of NAFLD. 
